Solaris Vaccines

Startup

Solaris Vaccines, Inc. was formed 2021 to address many of the challenges of creating vaccines in response to emerging threats to global human health. There are significant obstacles facing vaccines in that they: Are slow to develop and manufacture; Often have sub-optimal levels, broadness and duration of protection; Use archaic growth systems and/or potentially toxic chemicals; Rely on exotic and unproven methods; Have limited flexibility/coverage; Require challenging storage conditions and distribution channels; Face skepticism in general population.

The SolaVAX™ method employs the use of a photochemical (riboflavin/vitamin B2) in combination with UV light in the UVA and UVB wavelength regions to carry out specific nucleic acid alterations in pathogens, rendering them non-infective while maintaining authentic antigen presentation. Thus far the technology has been applied to the development of vaccines against dengue, influenza, SARS-CoV-2, and tuberculosis. The Company is interested in discussing opportunities to utilize the platform against other high value pathogens with prospective partners. We also are raising a Series A round and welcome interest from potential investors.